NASDAQ:PAVM - PAVmed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.33
  • Forecasted Upside: 430.79 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.57
▼ -0.04 (-2.48%)

This chart shows the closing price for PAVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PAVmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAVM

Analyst Price Target is $8.33
▲ +430.79% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $8.33, with a high forecast of $9.00 and a low forecast of $8.00. The average price target represents a 430.79% upside from the last price of $1.57.

This chart shows the closing price for PAVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in PAVmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/13/2021Maxim GroupReiterated RatingBuy$8.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
6/4/2021Maxim GroupReiterated RatingBuy$8.00High
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00High
2/22/2021Lake Street CapitalBoost Price TargetBuy$5.00 ➝ $9.00High
11/5/2020Ascendiant Capital MarketsInitiated CoverageBuy$5.00Medium
10/13/2020Lake Street CapitalInitiated CoverageBuy$5.00Medium
5/30/2020Maxim GroupReiterated RatingBuy$5.00Low
5/22/2020Maxim GroupReiterated RatingBuy$5.00N/A
4/17/2020Maxim GroupReiterated RatingBuy$5.00High
2/26/2020Maxim GroupReiterated RatingBuy$5.00High
11/22/2019Maxim GroupReiterated RatingBuy$3.00Low
8/16/2019Maxim GroupSet Price TargetBuy$3.00Low
5/23/2019Maxim GroupReiterated RatingBuyHigh
4/7/2019Maxim GroupReiterated RatingBuyMedium
1/14/2019Maxim GroupReiterated RatingBuy$3.00Medium
6/28/2018Maxim GroupInitiated CoverageBuy$5.00High
9/5/2017Dawson JamesReiterated RatingBuy$10.10High
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
PAVmed logo
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy, and Emerging Innovations. The GI health division comprises of EsoGuard esophageal DNA laboratory developed test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus technology. The minimally invasive interventions division offers CarpX minimally invasive surgical device for carpal tunnel syndrome. The infusion therapy division includes PortIO implantable intraosseous vascular accedd device and NextFlo highly accurate disposable intravenous infusion platform technology. The emerging innovations divisions consists of non-invasive laser-based glucose monitoring, single-use ventilators, resorbable pediatric ear tubes and mechanical circulatory cannulas. The company was founded on June 26, 2014 and is headquartered in New York, NY.
Read More

Today's Range

Now: $1.57
Low: $1.49
High: $1.62

50 Day Range

MA: $2.83
Low: $1.57
High: $4.26

52 Week Range

Now: $1.57
Low: $1.42
High: $9.70

Volume

1,339,502 shs

Average Volume

1,747,181 shs

Market Capitalization

$138.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Frequently Asked Questions

What sell-side analysts currently cover shares of PAVmed?

The following Wall Street sell-side analysts have issued research reports on PAVmed in the last twelve months: Cantor Fitzgerald, Lake Street Capital, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for PAVM.

What is the current price target for PAVmed?

3 Wall Street analysts have set twelve-month price targets for PAVmed in the last year. Their average twelve-month price target is $8.33, suggesting a possible upside of 430.8%. Lake Street Capital has the highest price target set, predicting PAVM will reach $9.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $8.00 for PAVmed in the next year.
View the latest price targets for PAVM.

What is the current consensus analyst rating for PAVmed?

PAVmed currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PAVM will outperform the market and that investors should add to their positions of PAVmed.
View the latest ratings for PAVM.

How do I contact PAVmed's investor relations team?

PAVmed's physical mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company's listed phone number is (212) 949-4319 and its investor relations email address is [email protected] The official website for PAVmed is www.pavmed.com.